Ryvu Therapeutics S.A.

WSE:RVU Stok Raporu

Piyasa değeri: zł1.0b

Ryvu Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Ryvu Therapeutics is forecast to grow earnings and revenue by 22.3% and 26.3% per annum respectively.

Anahtar bilgiler

22.3%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Life Sciences kazanç büyümesi26.4%
Gelir büyüme oranı26.3%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme06 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25
Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14
Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Kazanç ve Gelir Büyüme Tahminleri

WSE:RVU - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (PLN Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026176-53-182-572
12/31/2025169-79-159-852
12/31/2024126-102-162-1042
6/30/202482-96-102-92N/A
3/31/202474-94-103-95N/A
12/31/202367-92-93-85N/A
9/30/202384-73-60N/A
6/30/202388-66-23N/A
3/31/202380-75410N/A
12/31/202268-841521N/A
9/30/202250-94-51-44N/A
6/30/202237-105-68-58N/A
3/31/202236-92-80-69N/A
12/31/202135-79-71-59N/A
9/30/202126-72-74-58N/A
6/30/202125-61-61-37N/A
3/31/202130-41-38-5N/A
12/31/202037-32-45-11N/A
9/30/202038-40-57-23N/A
6/30/202041-32-74-51N/A
3/31/202017-41-36-17N/A
12/31/201934-44-41-17N/A
9/30/201953-53-55-27N/A
6/30/201919-60-38-6N/A
3/31/2019116-28-77-49N/A
12/31/201852-23-44-26N/A
9/30/2018492-22-7N/A
6/30/20189614-19-4N/A
3/31/201810221N/A22N/A
12/31/20171056N/A11N/A
9/30/201710413N/A7N/A
6/30/20179714N/A8N/A
3/31/20178010N/A-24N/A
12/31/2016663N/A-6N/A
9/30/2016600N/A-6N/A
6/30/201660-1N/A-10N/A
3/31/2016573N/A-14N/A
12/31/2015566N/A-16N/A
9/30/2015517N/A-10N/A
6/30/2015487N/A-8N/A
3/31/2015467N/A-5N/A
12/31/2014416N/A-5N/A
9/30/2014434N/A-6N/A
6/30/2014352N/A-5N/A
3/31/201427-1N/A-6N/A
12/31/201322-2N/A-7N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RVU is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: RVU is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: RVU is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: RVU's revenue (26.3% per year) is forecast to grow faster than the Polish market (4.3% per year).

Yüksek Büyüme Geliri: RVU's revenue (26.3% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if RVU's Return on Equity is forecast to be high in 3 years time

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y